FDA Clearance For DVS(R)-HFT, Next-Generation Wireless Sensor To Measure Actual Radiation Dose At Breast And Prostate Tumor Site

News — By on March 11, 2009 at 3:00 am

Sicel Technologies, Inc. announced it has received clearance from the U.S. Food and Drug Administration to begin marketing DVS®-HFT, the next-generation of the company’s original DVS (Dose Verification System) wireless implantable dosimeter that remains the only device to measure actual radiation dose at the tumor site for use in treating breast and prostate cancer patients undergoing external beam radiation therapy.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback